As stated above, IM is a Tyrosine kinase inhibitor (TKI) drug originally developed as an inhibitor for the BCR-ABL kinase, a fusion protein that causes chronic myeloid leukemia (CML), however IM also targets PDGF Receptors. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.